Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Adams D, et al. Among authors: Strahs AL. N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153. N Engl J Med. 2018. PMID: 29972753 Free article. Clinical Trial.
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A. Fitzgerald K, et al. Among authors: Strahs A. N Engl J Med. 2017 Jan 5;376(1):41-51. doi: 10.1056/NEJMoa1609243. Epub 2016 Nov 13. N Engl J Med. 2017. PMID: 27959715 Free PMC article. Clinical Trial.
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM, Siebers NM, Miller J, Strahs AL, Slichenmyer W. Cotreau MM, et al. Among authors: Strahs AL. Clin Pharmacol Drug Dev. 2015 Mar;4(2):137-42. doi: 10.1002/cpdd.145. Epub 2014 Oct 1. Clin Pharmacol Drug Dev. 2015. PMID: 27128217 Clinical Trial.
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Oldenhuis CN, Loos WJ, Esteves B, van Doorn L, Cotreau MM, Strahs AL, den Hollander MW, Gietema JA, de Vries EG, Eskens FA. Oldenhuis CN, et al. Among authors: Strahs AL. Clin Colorectal Cancer. 2015 Mar;14(1):18-24.e1. doi: 10.1016/j.clcc.2014.12.001. Epub 2014 Dec 16. Clin Colorectal Cancer. 2015. PMID: 25591799 Clinical Trial.
The effect of food on the pharmacokinetics of tivozanib hydrochloride.
Cotreau MM, Massmanian L, Strahs AL, Slichenmyer W, Vargo DL. Cotreau MM, et al. Among authors: Strahs AL. Clin Pharmacol Drug Dev. 2014 Mar;3(2):158-62. doi: 10.1002/cpdd.76. Epub 2013 Oct 30. Clin Pharmacol Drug Dev. 2014. PMID: 27128461
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE. Motzer RJ, et al. Among authors: Strahs A. J Clin Oncol. 2013 Oct 20;31(30):3791-9. doi: 10.1200/JCO.2012.47.4940. Epub 2013 Sep 9. J Clin Oncol. 2013. PMID: 24019545 Free PMC article. Clinical Trial.
A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.
Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN. Mayer EL, et al. Among authors: Strahs AL. Breast Cancer Res Treat. 2013 Jul;140(2):331-9. doi: 10.1007/s10549-013-2632-9. Epub 2013 Jul 19. Breast Cancer Res Treat. 2013. PMID: 23868188 Clinical Trial.
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF. Fishman MN, et al. Among authors: Strahs AL. Eur J Cancer. 2013 Sep;49(13):2841-50. doi: 10.1016/j.ejca.2013.04.019. Epub 2013 May 28. Eur J Cancer. 2013. PMID: 23726267 Free PMC article. Clinical Trial.
Reply to T.G. Karrison.
Nosov DA, Strahs AL. Nosov DA, et al. Among authors: Strahs AL. J Clin Oncol. 2013 Feb 20;31(6):814-5. doi: 10.1200/JCO.2012.46.4826. J Clin Oncol. 2013. PMID: 23544201 No abstract available.
26 results
Jump to page
Feedback